A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia

Exclusion Criteria

• •Patients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug, with the exception of hydroxyurea
• •History of allergic reactions attributed to components of cytarabine and/or the formulated product
• •Current evidence of CNS leukemia
• •Increased QTc interval (QTc \> 470 ms), baseline resting bradycardia \< 45 beats per minute, or baseline resting tachycardia \< 100 beats per minute
• •Family history of long QT syndrome or other risk factors for torsades de pointes, and/or the use of concomitant medications that prolong QT/QTc interval
• •Uncontrollable intercurrent illness
• •Pregnant or breast-feeding women
• •HIV-positive patients receiving anti-retroviral therapy
• •* Patients who refuse to potentially receive blood products and/or have a hypersensitivity to blood products